Department of Intensive Care, University Hospital of Foggia, Foggia, Italy.
General Surgery Unit, Department of Medical and Surgical Sciences, University Hospital of Foggia, Foggia, Italy.
Blood Purif. 2024;53(7):574-582. doi: 10.1159/000538870. Epub 2024 Apr 23.
Comparison of the marker kinetics procalcitonin, presepsin, and endotoxin during extracorporeal hemoperfusion with polymyxin-B adsorbing cartridge (PMX-HA) has never been described in abdominal sepsis. We aimed to compare the trend of three biomarkers in septic post-surgical abdominal patients in intensive care unit (ICU) treated with PMX-HA and their prognostic value.
Ninety abdominal post-surgical patients were enrolled into different groups according to the evidence of postoperative sepsis or not. Non-septic patients admitted in the surgical ward were included in C group (control group). ICU septic shock patients with endotoxin levels <0.6 EAA receiving conventional therapy were addressed in S group and those with endotoxin levels ≥0.6 EAA receiving treatment with PMX-HA, besides conventional therapy, were included in SPB group. Presepsin, procalcitonin, endotoxin and other clinical data were recorded at 24 h (T0), 72 h (T1) and 7 days (T2) after surgery. Clinical follow-up was performed on day 30.
SPB group showed reduced levels of the three biomarkers on T2 versus T0 (p < 0.001); presepsin, procalcitonin and endotoxin levels decreased, respectively, by 25%, 11%, and 2% on T1 versus T0, and 40%, 41%, and 26% on T2 versus T0. All patients in C group, 73% of patients in SPB group versus 37% of patients in S group survived at follow-up. Moreover, procalcitonin had the highest predictive value for mortality at 30 days, followed by presepsin.
The present study showed the reliability of presepsin in monitoring PMX-HA treatment in septic shock patients. Procalcitonin showed better predicting power for the mortality riSsk.
在腹部脓毒症中,从未描述过体外血液灌流与多粘菌素 B 吸附柱(PMX-HA)联合使用时降钙素原、促炎因子前蛋白(presepsin)和内毒素的标志物动力学比较。我们旨在比较重症监护病房(ICU)中接受 PMX-HA 治疗的手术后腹部脓毒症患者的三种生物标志物的趋势及其预后价值。
根据术后是否存在脓毒症的证据,将 90 名腹部手术后患者分为不同组。入住外科病房的非脓毒症患者纳入 C 组(对照组)。ICU 感染性休克患者,如果内毒素水平 <0.6 EAA,接受常规治疗,则归入 S 组;如果内毒素水平≥0.6 EAA,除常规治疗外,还接受 PMX-HA 治疗,则归入 SPB 组。在手术后 24 小时(T0)、72 小时(T1)和 7 天(T2)记录 presepsin、降钙素原、内毒素和其他临床数据。在第 30 天进行临床随访。
SPB 组与 T0 相比,T2 时三种生物标志物水平降低(p < 0.001);T1 时与 T0 相比,presepsin、降钙素原和内毒素水平分别降低 25%、11%和 2%,T2 时与 T0 相比,分别降低 40%、41%和 26%。C 组所有患者、SPB 组 73%的患者和 S 组 37%的患者在随访时存活。此外,降钙素原对 30 天死亡率的预测价值最高,其次是 presepsin。
本研究显示 presepsin 在监测脓毒性休克患者 PMX-HA 治疗中的可靠性。降钙素原对死亡率的预测能力更强。